Carlos Villalobos1. 1. Escuela de Ingeniería Comercial, Centro de Investigación en Economía Aplicada, Facultad de Economía y Negocios, Universidad de Talca, Talca, Chile.
Abstract
This paper provides an estimation of the accumulated detection rates and the accumulated number of infected individuals by the novel severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Worldwide, on July 20, it has been estimated above 160 million individuals infected by SARS-CoV-2. Moreover, it is found that only about 1 out of 11 infected individuals are detected. In an information context in which population-based seroepidemiological studies are not frequently available, this study shows a parsimonious alternative to provide estimates of the number of SARS-CoV-2 infected individuals. By comparing our estimates with those provided by the population-based seroepidemiological ENE-COVID study in Spain, we confirm the utility of our approach. Then, using a cross-country regression, we investigated if differences in detection rates are associated with differences in the cumulative number of deaths. The hypothesis investigated in this study is that higher levels of detection of SARS-CoV-2 infections can reduce the risk exposure of the susceptible population with a relatively higher risk of death. Our results show that, on average, detecting 5 instead of 35 percent of the infections is associated with multiplying the number of deaths by a factor of about 6. Using this result, we estimated that 120 days after the pandemic outbreak, if the US would have tested with the same intensity as South Korea, about 85,000 out of their 126,000 reported deaths could have been avoided.
This paper provides an estimation of the accumulated detection rates and the accumulated number of infected individuals by the novel severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Worldwide, on July 20, it has been estimated above 160 million individuals infected by SARS-CoV-2. Moreover, it is found that only about 1 out of 11 infected individuals are detected. In an information context in which population-based seroepidemiological studies are not frequently available, this study shows a parsimonious alternative to provide estimates of the number of SARS-CoV-2 infected individuals. By comparing our estimates with those provided by the population-based seroepidemiological ENE-COVID study in Spain, we confirm the utility of our approach. Then, using a cross-country regression, we investigated if differences in detection rates are associated with differences in the cumulative number of deaths. The hypothesis investigated in this study is that higher levels of detection of SARS-CoV-2 infections can reduce the risk exposure of the susceptible population with a relatively higher risk of death. Our results show that, on average, detecting 5 instead of 35 percent of the infections is associated with multiplying the number of deaths by a factor of about 6. Using this result, we estimated that 120 days after the pandemic outbreak, if the US would have tested with the same intensity as South Korea, about 85,000 out of their 126,000 reported deaths could have been avoided.
Governments and policymakers dealing with the COVID-19 pandemic will fail in their objectives if their actions are guided by misleading data or subsequent misinformation. The authorities should have reliable estimations of the number of SARS-CoV-2 infected individuals. However, there are few attempts to estimate the total amount of infections (1–5). Consequently, health systems face enormous challenges since an unknown and probably a high proportion of all SARS-CoV-2 infections remains undetected. Moreover, data suggest that infected individuals can be highly contagious before the onset of symptoms and SARS-CoV-2 can be also highly contagious in individuals who will never develop any symptoms (6–10).Undetected infections are dangerous because infectious individuals spread the coronavirus in unpredictable ways. Undetected infections consist of non-PCR-tested individuals with symptoms and asymptomatic individuals (non-COVID-19patients) that are likely to remain undetected over all phases of the infection. However, non-PCR-tested individuals with symptoms would tend to auto-select themselves, depending on the severity of their symptoms (from mild to severe), toward treatment and late detection. For this reason, it is important to know the proportion of the infected population which is asymptomatic or has such mild symptoms that self-select them into the group of non-PCR-tested individuals (11–15). Here, regarding the estimation of the number of infections, and for purposes of public health, I advocate the view by Amartya Sen and Martha Nussbaum that is preferable to be vaguely right than precisely wrong.The public health problem is that undetected asymptomatic individuals, as well as late-detected SARS-CoV-2 infected individuals, increase the risk for vulnerable groups. Since there is a transmission channel between the level of detection and the number of deaths, the early detection of asymptomatic infections, pre-symptomatic, and mild COVID-19 cases is a public health concern.Moreover, undetected cases also are responsible for the collapse of the health system by numerous aggravated and sometimes unexpected COVID-19patients requiring treatment in a short period. Overwhelmed health care systems reduce the recovery prospects of patients by the lack of treatment, undertreatment, increased risk of mistreatment of all patients, including those with COVID-19, and also put at unnecessarily risk the health workforce (21, 22).The problem is that many governments formulate their strategies and responses to the pandemic based on figures that they can control. This problem of reverse causality produces contra-productive incentives for governments since public opinion tends to negatively react to the report of the cumulative and the marginal numbers of detected (reported) cases. The contradiction is that something good, such as the increase in the testing efforts by governments can be perceived by the public opinion as something bad (due to the increase in detections). Worldwide, the media communicates confirmed cases and deaths as the relevant parameters to take into consideration when assessing the evolution of the pandemic. This is a mistake since this emphasis discourages governments from decidedly pushing for mass testing with the obvious consequence of an increased number of detected cases (although, as shown in this paper, there is a theoretical mechanism relating more testing with saving lives). More sophisticated observers would use the crude and adjusted case fatality ratios to assess the pandemic evolution. However, international comparisons show that crude and adjusted case fatality ratios are highly heterogeneous and their use can be misleading (23, 24). For instance, the simple division of the cumulative number of deaths by the cumulative number of confirmed cases underestimated the true case fatality ratio in past epidemics (24, 25). Although nowadays many case fatality ratios have been estimated in this pandemic correcting many of the observed past biases (26–28), they are still depending on testing efforts made by countries.The problem with heterogeneous case fatality ratios (different proportions of all cases that will end in death due to methodological differences on the denominator) is that they are not anchored at any exogenous information that allows researchers to perform international or territorial comparisons based on credible, and transparent assumptions. Consequently, to rely on the number of confirmed cases makes international comparations impossible since governments have shown to implement highly heterogeneous SARS-CoV-2 testing strategies ending up in different levels of location-based under-ascertainment.In an attempt to solve the mentioned problem, we anchor our analysis in the cumulative number of deaths, which is a statistic much more difficult to alter, in free societies, than the number of SARS-CoV-2 tests.We use this information together with the newest and sound estimates of the age-stratified infection fatality ratios (IFRs) provided in the recent SARS-CoV-2 related literature. In particular, we base our analysis on the IFR of 0.657% reported in Verity et al. (26). This IFR is very close to the 0.75% reported in a meta-analysis of 13 IFR estimates from a wide range of countries, and that were published between February and April of 2020 (30). We also assume orthogonal attack rates of the infection which is also supported by recent literature (16). By weighting the age-stratified IFRs by the country population age-groups shares in each country, it is possible to obtain country-specific IFRs.The relevance of this study is 3-fold: Firstly, the estimation of the true number of infections includes not only confirmed cases but COVID-19 undetected cases, as well as SARS-CoV-2-infected individuals without the disease, or in a pre-symptomatic stage. Therefore, to provide an estimation of the true number of SARS-CoV-2 infections is of more utility than to be only informed about the number of confirmed infections. This is because confirmed cases depend on the testing efforts that can be altered or even manipulated by governments. Moreover, one can compare the true estimate of infections with the number of COVID-19patients that require hospitalization. Such ratios can contribute to predicting, with exogenous-to-government information, shortages of the health systems. Secondly, the estimation of the true number of SARS-CoV-2 infections allows us to estimate the detection rate of the infection, which is a measure of the performance of health systems and governments while facing the pandemic. One can expect that higher levels of detection of SARS-CoV-2 infections, which includes asymptomatic population, and those in their early stages of the infection (which are more infectious) can reduce the risk exposure of the susceptible population with relatively a high risk of death, that is, the elderly and those individuals with preexisting conditions (17). Accordingly, a highly neglected statistic, such as the detection rate should be considered highly relevant from the public health point of view. Thirdly, in this paper, we test the hypothesis that higher detection rates can save lives while providing a measure of this impact (having in mind that is preferable to be vaguely right than precisely wrong). Thus, this study aims to quantify the importance of testing while providing empirical support to the utility of implementing massive SARS-CoV-2 tests.Overall, this study argues that it is crucial to compute the evolution of the cumulative number of estimated SARS-CoV-2 infected individuals, and subsequently, the cumulative detection rates. This information would provide public health managers and governments the incentives to improve detection rates, rather than to the opposite. Moreover, the identification strategy can be used at lower levels of aggregation, such as regions, provinces, and municipalities to improve responses to the pandemic, including the planning of selective lockdowns or spatial-selective enhancements of the installed critical care units.In summary, this study proposes a baseline estimation of the number of SARS-CoV-2 infections and detection rates based on current information and transparent assumptions. However, the assumptions discussed later in this paper can be later modified to match the current scientific available evidence and country-specific developments and contexts.
Data and Methods
Data
For this research, we use the cumulative number of deaths and confirmed cases in the world and by country, published by OurWorldInData.org, a project of the Global Change Data Lab with the collaboration of the Oxford Martin Programme on Global Development at the University of Oxford. Age-stratified demographic proportions of the population were obtained from the UN population data. The age-stratified IFRs are those reported in Verity et al. (26). Our method also requires to know the distribution of the number of days between infection and death. Since this number is unknown, we approach to this number using the sum of the median incubation period as reported in Lauer et al. (31), and the mean number of days between the onset of symptoms and death as reported in Verity et al. (26). For our empirical exercise, we rely on World Development data by the World Bank (GDP per capita and health expenditure as a share of the GDP) and in World Health Organization data for BCG vaccination.In this study, our regression analysis relies on data for 91 countries covering above 86% of the world population. The remaining countries were excluded because they either do not have significant mortality figures (for instance Uruguay, Monaco, Bermuda, etc.), or full data.
Methods
Estimation Strategy
In this study, we rely on a very simple rationale. At a given point in time, the cumulative number of deaths should be a proportion of the cumulative number of infections somewhat in the past. But how many days in the past? The answer lies in the sum of the number of days of incubation and the number of days between the onset of symptoms and death. This rationale follows a report focusing on the 40 most-affected countries by the pandemic in the world (32). However, in this paper, we deviated from the mentioned report by using the key parameters in a different way, which translated into a different estimation of the number of infected individuals.On average, deaths occur ~18 days (17.8 days with 95% credible interval [CrI] 16.9–19.2) after the onset of COVID-19 symptoms (26), while the incubation period of COVID-19 has been estimated in about 5 days (5.1 days with 95% CI, 4.5–5.8) as reported in Lauer et al. (31). Thus, by comparing the cumulative number of deaths at time t in country i (cdeaths() with the country-specific infection fatality ratio (ifr), which is assumed constant over time, it is possible to obtain a rough approximation of the cumulative number of SARS-CoV-2 infections 23 days (18 days + 5 days) in the past (cinfected().Additionally, we use the ratio between the cumulative number confirmed (detected) cases at time t−23 in country i (cconfirmed() and the cumulative number of infected individuals (cinfected() at time t−23 in country i as a rough measure of the cumulative rate of detection of SARS-CoV-2 infections at time t−23.
Infection Fatality Ratio
In order to estimate the country-specific infection fatality ratio for country i used in equation 1, we weight the age-stratified infection fatality ratios reported in Verity et al. (26), by the age-group population shares of country i. The calculation of the age-stratified infection fatality ratios relies on two assumptions that can be modified when producing point estimates of the number of individuals affected by a SARS-CoV-2 infection. Firstly, it assumes that there are no cross-country differences in the average overall health status of the population, comorbidity, or in the soundness of the different health systems. In absence of standardized country-specific information of these variables, this assumption is convenient although, at first sight, it can be considered a restrictive one. However, it is quite the opposite since, in richer countries with higher proportions of elderly populations, the estimated infectionmortality ratios are likely to be overestimated. If so, our estimates of the infected population represent a lower limit of the true number of infections. The second assumption is that the attack rate of the coronavirus is unrelated to the age and sex of susceptible individuals. This is in concordance with the evidence in respiratory infections in previous pandemic processes (26, 33). Then, the distribution of IFRs across countries reflects the “fixed” lethality of the virus associated to a varying demographic structure of the population across the world.Figure 1 presents the calculated infection fatality ratios for the world, and for 50 countries in which the lethality of the pandemic has been more significant.
Figure 1
Infection fatality ratios (selected countries, in percentage). Source: Own elaboration.
Infection fatality ratios (selected countries, in percentage). Source: Own elaboration.Recently, a cross-sectional epidemiological study with a super-spreading event in the county of Heinsberg in Germany offered the opportunity to estimate the infection fatality ratio in the community (34). The estimated infection fatality ratio was 0.36%. Although this number is surprisingly low when compared with other estimations, for instance, the used in this study for Germany (1.3%), it is not evident that the true infection fatality ratio is closer to 0.36% rather than 1.3%. This is because there can be local factors that explain the discrepancy as pointed out in the Heinsberg study. Amongst these factors, it might be mentioned comorbidity gaps, ethnic differences, the quality and coverage of the health systems, climatic differences, immunization levels, etc..Consequently, it might be necessary to assess the consequences of using an overestimated infection fatality ratio (that is, an IFR closer to the one reported in the Heinsberg study, or others inferred from seroprevalence data (36). The answer is that the number of infections would be underestimated, and that detection rates would be overestimated (since the infection fatality ratio is on the denominator). An overestimation of the detection rates reduces the validity of international rankings based on this figure. However, from the public health point of view, this would be irrelevant since, as discussed later, all countries should increase their detection rates of SARS-CoV-2 infections as much as possible.
Regression Analysis
To investigate whether improving the detection rates of SARS-CoV-2 infections is potentially associated to save lives, we use a parsimonious synchronic cross-country multiple linear regression. That is, we use the information reported 15, 60, and 105 days after the confirmation of the first 100 SARS-CoV-2 infections, which corresponds to the pandemic outbreak (PO). At a given pandemic phase, we regress the natural logarithm of the cumulative number of deaths in country i, ln(deaths), on their estimated detection rates (DR) and its squared to assess whether there is a non-linear relationship of this conditional correlation.The four parsimonious regressions have a demographic control that corresponds to the estimated country-specific infection fatality ratio (ifr). This is a non-endogenous control since it only captures the impact of demography (population shares by age-groups) on the number of deaths and not the reverse. The regressions control for the population size of the country i in its natural logarithmic form ln(pop). This control is necessary because the share of the susceptible population remains persistently at relatively higher levels in more populated countries when compared with the less populated ones. We also include the natural logarithm of the number of confirmed SARS-CoV-2 infections in each country ln(confirmed). This is a measure of the persistence of the mortality process while controlling for cross-country differences in their absolute testing performances. The regressions also control for the economic performance of a country by means of the natural logarithm of the per capita gross domestic product ln(gdppc). We also include the current health expenditure as share of GDP in 2017 (healthshare). This control is needed to account for relative resource-dependent differences in the coverage/quality of the health systems around the globe. Finally, we use available data to explore a possible association between BCG vaccination and aggravated cases of COVID-19, and deaths [a relationship which is being investigated in some clinical trials (37)]. The evidence is still inconclusive because the argued existence of uncontrolled confounders (38–42). However, if these confounders exist, they can bias the relationship between SARS-CoV-2 detections rates and the cumulative number of deaths. Based on this argument, we include a raw of dummies capturing the degree of BCG vaccination coverage as follows: BGC group 1: no mandatory vaccination (up to 49.9% coverage), BGC group 2: 50 to 79.9% coverage, BGC group 3: 80 to 89.9%, BGC group 4: 90 to 98.9%, and BGC group 5: 99 to 100%. The reference category is BCG group 1.
Robustness
An alternative approach is used to indirectly investigate the conditional association between detection rates and SARS-CoV-2 related deaths. Instead of using the detection rates and its square, we use the natural logarithm of the estimated number of infections ln(infections) while dropping from the equation the natural logarithm of the number of confirmed (detected) SARS-CoV-2 infections as follows:Regarding the statistical inference, significance tests rely on a heteroscedasticity consistent covariance matrix (HCCM) type HC3 which is suitable when the number of observations is small (43). Although in the presence of heteroscedasticity of unknown form, Ordinary Least Square estimates are unbiased, the inference can be misleading due to the fact that the usual tests of significance are generally inappropriate (43).Additionally, we estimate the same set of equations (the main specification and the robustness specification 15, 60, and 105 days after the pandemic outbreak) using robust regressions. We do this because we have the concern that parameter estimates may be biased if, in some countries (outliers), the report of the cumulative number of deaths has been involuntarily altered or even manipulated. Robust regression resists the effect of such outliers, providing better than OLS efficiency when heavy-tailored error distributions exist as it can be likely the case (44).
Results
Descriptive Analysis
On July 20, the estimated infected population reaches about 160 million individuals (Figure 2A). This number is about 19 times larger than the reported number of confirmed cases (about 8.6 million represented by the dashed line). Note that the number of infections is estimated based on detection rates calculated 23 days in the past. Thus, for the period t−23 to t, the number of SARS-CoV-2 infected individuals are estimated using the estimation rate as in t−23. Therefore, the estimation of SARS-CoV-2 infected individuals can be biased if detection rates deteriorate or improve considerably within this time span.
Figure 2
Estimates of the number of SARS-CoV-2 infections and the estimated detection rate in the World. (A) Estimated and confirmed infected population. (B) Estimated Global detection rate. Note that (B) depicts the detection rates until t−23. Both panels display 95% confidence intervals. Source: Own elaboration.
Estimates of the number of SARS-CoV-2 infections and the estimated detection rate in the World. (A) Estimated and confirmed infected population. (B) Estimated Global detection rate. Note that (B) depicts the detection rates until t−23. Both panels display 95% confidence intervals. Source: Own elaboration.The accuracy of our estimations can be assessed by contrasting them against to those provided by population-based seroepidemiological studies. There are some studies of this type focusing on restricted geographical areas, for instance, in Germany and Switzerland (34, 45). However, to the best of our knowledge, there is only one country level and large scale population-based seroepidemiological study performed in Spain (46). The ENE-COVID study in Spain finds that, on 11 May, 5% of the population would test IgG positive against SARS-CoV-2. It implies that about 2.35 million individuals were infected by SARS-CoV-2. Similarly, in our study we estimated on 11 May an infected population of about 2.25 million individuals. This evidence suggests that our method can be a suitable alternative when population-based seroepidemiological studies are not available, which is frequently the case. Here, it is important to recognize that, from the public health point of view, it is preferable to be vaguely right than precisely wrong. On 11 May, Spain confirmed only 246,504 cases (about 10% of all estimated infections). At that time, it would have been convenient that public health authorities and the public opinion would have the information that, for each confirmed case, there were significantly much more individuals spreading the infection in unpredictable ways.Back to the global estimates, by comparing the cumulative number of estimated infections with the cumulative number of confirmed (detected) cases, we obtain, at the end of June 2020, a global detection rate of about 9% (Figure 2B). The global detection rate curve shows an U-shape with a minimum at the beginning of the third week of March reaching only 1.1%. The last data suggest that detection rates are steadily increasing. Moreover, the semi-logarithmic plot in Figure 2A suggests that the infection stopped spreading at its maximum pace approximately during the third week of March, but unfortunately, it increased its speed again around the last week of June.The world distribution of the number of deaths, the estimated number of SARS-CoV-2 infections, and the detection rates of SARS-CoV-2 infections across the world are displayed in Figures 3–5, respectively.
Figure 3
World distribution of deaths as of 20 July 2020. Source: Own Elaboration.
Figure 5
World distribution of the estimated detection rates of SARS-CoV-2 infections as of 20 July 2020 (in percentage). Source: Own Elaboration.
World distribution of deaths as of 20 July 2020. Source: Own Elaboration.World distribution of the estimated number of SARS-CoV-2 infections as of 20 July 2020. Source: Own Elaboration.World distribution of the estimated detection rates of SARS-CoV-2 infections as of 20 July 2020 (in percentage). Source: Own Elaboration.Since the global estimates are no more than an aggregation of the trajectories made by the different countries in the world, we investigate how heterogeneous the detection rates across countries are. Table 1 presents this information in a synchronic way. The rankings compare countries in the same phase of their respective pandemic processes, that is after 15, 30, 45, 60, 75, and 90 days after the confirmation of the first 100 SARS-CoV-2 infections (pandemic outbreak). This approach allows us to perform such an international comparison.
Table 1A
Synchronic descriptive statistics (15, 30, and 45 days after the pandemic outbreak).
Country/Days since the first 100 cases were confirmed
Detection rankings
Confirmed Cases (in thousands)
Estimated Cases (in thousands)
Estimated detection rate (Percentage)
Number of deaths (Count)
15
30
45
15
30
45
15
30
45
15
30
45
15
30
45
South Korea
1
2
3
6.3
8.8
10.2
15.8
22.5
25.3
39.8
39.1
40.4
42
103
183
Australia
2
1
1
1.8
6.0
6.7
6.7
9.7
10.4
27.3
61.1
64.1
7
45
74
Luxembourg
3
6
7
2.2
3.4
3.8
9.3
11.2
12.3
23.3
30.0
30.9
23
69
90
Thailand
4
3
2
1.4
2.6
2.9
6.0
6.9
7.0
23.0
37.8
41.7
7
41
54
Lithuania
5
5
12
0.8
1.3
1.4
3.4
4.1
5.4
23.0
32.4
26.3
9
36
46
Croatia
6
12
13
1.0
1.8
2.1
4.5
7.4
8.3
22.6
24.4
25.3
7
36
77
Estonia
7
8
8
0.6
1.3
1.6
3.4
4.7
5.5
18.7
27.9
30.1
1
25
50
Norway
8
7
6
1.7
5.5
7.1
10.2
19.2
22.7
17.0
28.7
31.2
7
50
154
Finland
9
24
23
1.0
2.8
4.5
7.2
18.4
24.0
13.3
15.0
18.6
4
48
186
Israel
10
4
5
3.0
10.7
15.4
24.2
33.1
39.0
12.5
32.5
39.5
10
101
199
Czech R.
11
10
11
2.1
5.7
7.4
16.6
22.7
27.2
12.4
25.3
27.1
9
119
218
Japan
12
21
30
0.4
1.0
3.7
3.4
6.8
24.2
12.1
15.4
15.1
6
36
73
Greece
13
15
18
0.9
2.0
2.5
7.8
10.8
12.3
11.4
18.7
20.3
26
90
130
Chile
14
13
24
2.4
7.9
14.9
21.7
38.7
85.5
11.3
20.5
17.4
8
92
216
Austria
15
11
10
3.6
12.3
14.8
33.4
50.4
54.4
10.9
24.4
27.3
16
220
463
Bosnia & H.
16
31
33
0.7
1.3
1.9
6.1
11.9
15.1
10.8
11.0
12.9
24
48
79
Albania
17
18
17
0.4
0.6
0.8
3.6
3.6
3.9
10.4
16.8
21.6
22
26
31
Slovenia
18
25
28
0.6
1.2
1.4
6.3
8.2
8.8
10.1
14.5
16.0
9
50
82
Bulgaria
19
30
31
0.5
0.8
1.6
4.7
7.7
11.0
9.8
11.0
14.5
10
41
72
Puerto Rico
20
26
22
0.8
1.4
2.3
8.1
10.3
11.6
9.8
13.3
19.4
42
84
113
Cuba
21
19
19
0.6
1.4
1.8
7.3
8.4
8.8
8.5
16.3
20.2
16
54
77
Malaysia
22
16
16
1.5
4.0
5.5
18.3
22.5
24.7
8.3
17.6
22.4
14
63
93
Tunisia
23
29
37
0.6
0.9
1.0
7.2
8.1
8.7
8.2
11.1
11.8
22
38
44
Serbia
24
9
4
1.2
5.7
9.4
14.7
20.9
23.2
8.0
27.3
40.3
31
110
189
Portugal
25
14
14
4.3
16.0
23.9
54.1
80.5
94.5
7.9
19.8
25.3
76
470
903
Suriname
26
–
–
0.3
–
–
3.9
–
–
7.8
–
–
8
–
–
Switzerland
27
17
20
4.8
20.2
27.7
75.8
119.4
137.7
6.4
16.9
20.1
43
540
1,134
Moldova
28
35
39
1.0
2.6
4.5
15.4
26.9
39.9
6.3
9.7
11.2
19
73
143
South Africa
29
51
58
1.4
2.6
6.0
22.3
52.4
121.0
6.2
5.0
4.9
5
48
116
Ukraine
30
23
21
1.7
7.6
14.2
28.4
50.6
72.0
5.9
15.1
19.7
52
193
361
Nicaragua
31
39
–
1.1
2.0
–
19.8
24.4
–
5.6
8.3
–
46
64
–
Macedonia
32
33
42
0.5
1.2
1.5
8.7
11.6
14.9
5.6
10.6
10.2
17
54
86
Denmark
33
28
26
1.5
5.1
7.9
27.2
39.7
47.2
5.4
12.8
16.8
24
203
384
El Salvador
34
41
34
0.2
0.7
1.7
4.7
8.7
14.0
5.0
8.0
12.3
8
15
33
Libya
35
53
–
0.4
0.7
–
8.3
16.5
–
4.7
4.2
–
5
18
–
Panama
36
36
36
1.3
4.0
6.7
28.5
43.9
56.6
4.6
9.2
11.9
32
109
192
Poland
37
34
32
1.6
6.7
11.9
35.7
67.3
90.4
4.6
9.9
13.2
18
232
562
Argentina
38
47
51
1.1
2.7
4.7
27.6
44.7
69.6
4.1
5.9
6.7
34
122
237
Bangladesh
39
43
45
2.9
10.9
26.7
73.0
151.7
297.2
4.0
7.2
9.0
101
183
386
Russia
40
27
9
2.3
24.5
106.5
60.6
188.2
370.0
3.9
13.0
28.8
17
198
1,073
Guatemala
41
66
79
0.4
0.9
3.1
10.2
33.4
123.4
3.8
2.7
2.5
11
24
55
China
42
20
25
14.4
70.6
80.3
383.7
455.1
473.8
3.8
15.5
16.9
304
1,771
2,946
Romania
43
38
40
1.5
6.3
11.3
41.4
75.9
104.7
3.5
8.3
10.8
29
306
631
Turkey
44
32
29
15.7
74.2
122.4
471.0
677.4
786.3
3.3
11.0
15.6
277
1,643
3,258
Saudi Arabia
45
44
27
1.2
4.9
20.1
38.6
74.0
124.3
3.2
6.7
16.2
8
65
152
Germany
46
22
15
3.8
57.3
125.1
123.2
374.0
545.7
3.1
15.3
22.9
8
455
2,969
Haiti
47
37
38
0.5
2.5
4.7
17.5
29.0
40.8
3.0
8.6
11.5
21
48
82
Ireland
48
46
41
2.4
9.7
19.6
81.9
159.7
187.4
2.9
6.0
10.5
36
334
1,102
Morocco
49
42
35
1.0
3.0
5.2
34.8
39.6
42.6
2.9
7.7
12.3
70
143
191
South Sudan
50
40
43
0.3
1.3
1.9
12.0
16.4
18.7
2.8
8.0
10.1
6
14
34
Dominican R.
51
49
46
1.6
4.7
8.2
57.9
83.7
98.7
2.7
5.6
8.3
77
226
346
Canada
52
45
48
3.4
20.7
43.9
125.1
340.8
552.5
2.7
6.1
7.9
35
509
2,302
Hungary
53
52
53
0.7
1.9
3.0
25.5
38.6
45.9
2.7
5.0
6.6
32
189
351
Colombia
54
56
55
1.1
3.2
7.0
40.2
79.5
130.0
2.6
4.1
5.4
17
144
314
Niger
55
77
81
0.6
0.8
0.9
26.7
36.6
37.7
2.4
2.1
2.4
19
36
55
Pakistan
56
64
62
1.6
6.0
15.8
71.6
203.6
377.3
2.3
2.9
4.2
18
107
346
U. Arab E.
57
48
44
0.7
5.4
12.5
29.5
91.6
128.4
2.3
5.9
9.7
6
33
105
Sweden
58
60
56
1.6
6.4
14.4
77.9
197.1
287.1
2.1
3.3
5.0
16
373
1,540
Ecuador
59
74
64
2.3
7.9
24.9
118.0
359.2
652.6
2.0
2.2
3.8
79
388
900
Somalia
60
61
61
0.6
1.4
2.0
31.8
43.8
46.9
1.9
3.1
4.2
28
55
78
Bolivia
61
71
68
0.4
1.1
3.1
19.7
46.5
92.4
1.8
2.3
3.4
28
55
142
Burkina Faso
62
76
80
0.4
0.6
0.7
25.5
29.5
30.7
1.6
2.1
2.4
23
41
48
Honduras
63
87
76
0.4
0.7
2.0
24.8
44.4
70.7
1.6
1.5
2.8
25
61
116
Iraq
64
62
73
0.5
1.4
1.8
36.3
44.6
61.2
1.5
3.1
3.0
42
78
88
Sierra Leone
65
63
67
0.3
0.8
1.1
23.0
26.0
30.4
1.5
3.0
3.6
20
45
50
Kenya
66
86
85
0.2
0.4
0.8
16.1
27.4
45.7
1.5
1.5
1.8
11
21
50
Cameroon
67
73
77
0.8
1.8
2.8
57.1
82.5
107.3
1.4
2.2
2.6
12
59
136
D. R. Congo
68
79
71
0.3
0.6
1.4
19.3
31.1
42.0
1.4
1.8
3.3
22
31
61
Algeria
69
72
70
1.3
2.7
4.8
102.5
122.5
147.8
1.3
2.2
3.3
152
384
470
Mauritania
70
59
65
0.7
2.2
4.5
53.4
64.6
120.3
1.3
3.4
3.7
31
95
129
Netherlands
71
54
50
3.0
16.6
32.7
239.8
395.9
482.8
1.2
4.2
6.8
106
1,651
3,684
Iran
72
68
59
9.0
29.4
68.2
733.6
1,167.9
1,440.0
1.2
2.5
4.7
354
2,234
4,232
Mali
73
85
86
0.4
0.7
1.1
30.9
46.3
63.5
1.2
1.5
1.7
21
38
67
Chad
74
80
84
0.5
0.8
0.9
41.2
43.5
43.5
1.2
1.8
2.0
50
65
73
Afghanistan
75
83
74
0.6
1.5
4.7
48.8
96.5
159.4
1.1
1.6
2.9
18
57
122
Peru
76
58
54
1.1
11.5
37.0
106.5
319.1
627.9
1.0
3.6
5.9
30
254
1,051
Sudan
77
84
82
0.8
2.7
5.5
80.1
177.8
234.9
1.0
1.5
2.3
45
111
314
Philippines
78
67
69
1.1
4.6
7.8
118.9
177.0
234.0
0.9
2.6
3.3
68
297
511
Brazil
79
81
83
3.9
22.2
66.5
433.6
1,333.9
3,175.9
0.9
1.7
2.1
114
1,223
4,543
Indonesia
80
75
72
1.3
4.6
9.5
148.1
215.2
307.2
0.9
2.1
3.1
114
399
773
Italy
81
55
52
7.4
63.9
135.6
899.6
1,566.6
2,024.0
0.8
4.1
6.7
366
6,077
17,129
Spain
82
50
47
9.2
94.4
181.5
1,205.5
1,865.5
2,182.4
0.8
5.1
8.3
309
8,189
18,893
India
83
69
66
1.3
11.4
33.1
164.6
456.0
899.4
0.8
2.5
3.7
32
377
1,074
Egypt
84
82
78
0.6
2.2
5.0
77.0
136.9
203.1
0.7
1.6
2.5
36
164
359
Belgium
85
65
57
2.3
18.4
38.5
316.7
634.0
770.7
0.7
2.9
5.0
37
1,283
5,683
Nigeria
86
88
75
0.3
1.5
5.0
54.2
111.0
175.1
0.6
1.4
2.8
10
44
164
France
87
70
60
4.5
40.2
98.1
742.3
1,732.2
2,149.8
0.6
2.3
4.6
91
2,606
14,967
Mexico
88
89
87
1.4
6.3
20.7
251.9
691.8
1,525.6
0.5
0.9
1.4
37
486
1,972
U.K.
89
78
63
3.3
38.2
114.2
907.2
1,904.7
2,945.9
0.4
2.0
3.9
144
3,605
15,464
U.S.
90
57
49
4.7
189.6
639.7
1,547.1
5,216.8
8,058.6
0.3
3.6
7.9
85
4,079
30,985
Yemen
91
90
88
0.3
0.7
1.1
126.8
170.9
242.1
0.2
0.4
0.5
66
160
302
This ranking is made up of all countries with more than 30 deaths due to COVID-19 40 days after the pandemic outbreak. Countries are ranked by their detection rates 15 days after the pandemic outbreak. Missing values in this table indicate that the country has not reached the requested number of days after its pandemic outbreak. Source: Own elaboration.
Synchronic descriptive statistics (15, 30, and 45 days after the pandemic outbreak).This ranking is made up of all countries with more than 30 deaths due to COVID-19 40 days after the pandemic outbreak. Countries are ranked by their detection rates 15 days after the pandemic outbreak. Missing values in this table indicate that the country has not reached the requested number of days after its pandemic outbreak. Source: Own elaboration.Synchronic descriptive statistics (60, 75, and 90 days after the pandemic outbreak).This ranking is made up of all countries with more than 30 deaths due to COVID-19 40 days after the pandemic outbreak. Countries are ranked by their detection rates 15 days after the pandemic outbreak. Missing values in this table indicate that the country has not reached the requested number of days after its pandemic outbreak. Source: Own elaboration.At a first sight, it is noteworthy the fact that each of the first 24 countries ranked on the top by the initial detection rate (15 days after the beginning of the pandemic outbreak) does not accumulate more than 500 deaths 45 days after initiating their pandemic processes. Thus, it seems to exist a strong correlation between detection rates and the cumulative number of deaths for a given stage of the pandemic process. Countries with high counts of deaths ranked very badly in their initial detection rates. For example, the US, Spain, Italy, UK, France, and Belgium ranked in place 90, 82, 81, 89, 87, and 85, out of 91 countries listed in the ranking.A second conclusion is that the relative improvement of detection rates over time, that is, 30, 45, 60, 75, and 90 days after the beginning of the pandemic processes, does not alter the fact that those countries are still ranked the worst in terms of deaths. That is, improving detection over time has declining returns to scale when comes to save lives.The depicted relationship between detection rates and the cumulative number of deaths remains almost unchanged when using non-synchronic data as of 20 May in Table 2. This table mixes information of countries at different stages from their pandemic processes. So, it must be interpreted with caution. Although efforts to increase detection have been significative in the above-mentioned countries, none of them is still ranked on the top part of the ranking with 91 countries for which we have full data (US in ranking 36, Spain 45, Italy 46, Belgium 55, UK 56, and France in place 58). Similarly, in this non-synchronic ranking, with the exception of Russia, none of the first 10 countries accumulated more than 500 deaths on May 20.
Table 2
Non-synchronic descriptive statistics as of 20 May.
Country
Detection rate ranking
Confirmed Cases
Estimated Cases
Number of Deaths
Detection rate (Percentage)
Country
Detection rate ranking
Confirmed Cases
Estimated Cases
Number of Deaths
Detection rate (Percentage)
Australia
1
7,068
10,803
99
65.4
Macedonia
47
1,839
20,629
106
8.9
Serbia
2
10,733
24,472
234
43.9
Bangladesh
48
25,121
284,758
370
8.8
Russia
3
299,941
713,396
2,837
42.0
Peru
49
99,483
1,137,309
2,914
8.7
Thailand
4
3,034
7,293
56
41.6
Netherlands
50
44,249
529,581
5,715
8.4
Israel
5
16,650
42,239
277
39.4
Argentina
51
8,796
114,004
393
7.7
South Korea
6
11,110
28,757
263
38.6
Sweden
52
30,799
417,234
3,743
7.4
Norway
7
8,257
24,041
233
34.3
Hungary
53
3,598
50,265
470
7.2
Luxembourg
8
3,958
12,368
109
32.0
Colombia
54
16,935
256,149
613
6.6
Estonia
9
1,791
5,891
64
30.4
Belgium
55
55,791
847,676
9,108
6.6
Czech R.
10
8,647
30,105
302
28.7
U.K.
56
248,818
3,792,371
35,341
6.6
Japan
11
16,385
57,455
771
28.5
Iran
57
124,603
1,992,740
7,119
6.3
Austria
12
16,257
58,599
632
27.7
France
58
143,427
2,444,441
28,022
5.9
Malaysia
13
6,978
26,056
114
26.8
Pakistan
59
45,898
844,102
985
5.4
Germany
14
176,007
671,716
8,090
26.2
India
60
106,750
2,054,585
3,303
5.2
Portugal
15
29,432
113,959
1,247
25.8
South Africa
61
17,200
363,475
312
4.7
Lithuania
16
1,562
6,060
60
25.8
Philippines
62
12,942
287,923
837
4.5
Croatia
17
2,232
8,763
96
25.5
Libya
63
68
1,544
3
4.4
Finland
18
6,399
26,036
301
24.6
Ecuador
64
34,151
784,137
2,839
4.4
Puerto Rico
19
2,805
11,951
124
23.5
Algeria
65
7,377
173,847
561
4.2
Albania
20
949
4,088
31
23.2
Brazil
66
271,628
6,890,826
17,971
3.9
Ukraine
21
18,876
86,905
548
21.7
Bolivia
67
4,481
115,342
189
3.9
Denmark
22
11,044
52,134
551
21.2
Indonesia
68
18,496
480,800
1,221
3.8
Cuba
23
1,887
8,926
79
21.1
D. R. Congo
69
1,731
47,886
61
3.6
Greece
24
2,840
13,671
165
20.8
Somalia
70
1,502
44,338
59
3.4
Switzerland
25
30,535
147,794
1,613
20.7
South Sudan
71
285
8,421
6
3.4
Saudi Arabia
26
59,854
303,501
329
19.7
Egypt
72
13,484
401,828
659
3.4
Turkey
27
151,615
862,911
4,199
17.6
Honduras
73
2,955
88,824
147
3.3
Poland
28
19,268
114,170
948
16.9
Afghanistan
74
7,653
230,911
178
3.3
U. Arab E.
29
25,063
150,496
227
16.7
Nigeria
75
6,401
203,510
192
3.1
Bulgaria
30
2,292
14,227
116
16.1
Cameroon
76
3,529
113,118
140
3.1
Slovenia
31
1,467
9,206
104
15.9
Haiti
77
596
19,339
22
3.1
Morocco
32
7,023
44,481
193
15.8
Burkina Faso
78
806
30,682
52
2.6
Bosnia & H.
33
2,319
15,813
133
14.7
Suriname
79
11
429
1
2.6
Chile
34
49,579
359,514
509
13.8
Niger
80
914
37,746
55
2.4
Romania
35
17,191
125,640
1,126
13.7
Sierra Leone
81
534
24,508
33
2.2
U.S.
36
1,528,568
11,884,244
91,921
12.9
Guatemala
82
2,133
103,309
43
2.1
Panama
37
9,867
77,349
281
12.8
Kenya
83
963
49,412
50
1.9
China
38
84,065
667,702
4,638
12.6
Iraq
84
3,611
199,779
131
1.8
Moldova
39
6,340
51,912
221
12.2
Mexico
85
54,346
3,289,790
5,666
1.7
Ireland
40
24,251
203,128
1,561
11.9
Mali
86
901
57,558
53
1.6
Tunisia
41
1,044
8,865
47
11.8
Sudan
87
2,591
169,575
105
1.5
El Salvador
42
1,498
12,905
31
11.6
Chad
88
545
42,352
56
1.3
Dominican R.
43
13,223
116,836
441
11.3
Mauritania
89
81
27,361
4
0.3
Canada
44
79,101
763,889
5,912
10.4
Yemen
90
167
67,359
28
0.2
Spain
45
232,555
2,247,533
27,888
10.3
Nicaragua
91
25
14,739
8
0.2
Italy
46
226,699
2,472,703
32,169
9.2
Countries are ranked by the detection rates of SARS-CoV-2 infections as of 20 May. Source: Own elaboration.
Non-synchronic descriptive statistics as of 20 May.Countries are ranked by the detection rates of SARS-CoV-2 infections as of 20 May. Source: Own elaboration.In Table 3, we present the non-synchronic ranking as of 22 June. The US is in place 35, Spain 49, Italy 53, Belgium 63, UK 61, and France 67. It is noteworthy that, except for Russia, none of the first 16 countries in this ranking have accumulated more than 2,000 fatalities on 22 June. More importantly and despite the incredible efforts to increase the tests amongst the more developed countries, none of them were able to detect more than 16% of the estimated infections (the US detected 15.7% on 22 June). It implies that testing efforts need to be deployed at the first stages of the pandemic process due to its cumulative nature. Tables 2, 3 show that moving over time from relatively low to relatively high cumulative detection rates is unlikely and probably very expensive. This is due to the over proportional efforts needed to expand testing relative to the exponentially growing infections at the early stages of the pandemic. Consequently, from the public health point of view, it is much more advantageous, technically, and economically feasible, to implement mass testing from the very beginning of the pandemic process. To achieve this goal, health authorities and governments would require understanding the linkages between the cumulative detection rates and the minimization of the pandemic related fatalities and economic damage.
Table 3
Non-synchronic descriptive statistics as of 22 June.
Country
Detection rate ranking
Confirmed Cases
Estimated Cases
Number of Deaths
Detection rate (Percentage)
Country
Detection rate ranking
Confirmed Cases
Estimated Cases
Number of Deaths
Detection rate (Percentage)
Australia
1
7,461
11,478
102
65.0
Sweden
47
56,043
479,232
5,053
11.7
Russia
2
584,680
1,271,052
8,111
46.0
Peru
48
254,936
2,272,406
8,045
11.2
Puerto Rico
3
6,525
14,521
149
44.9
Spain
49
246,504
2,357,978
28,324
10.5
Thailand
4
3,148
7,301
58
43.1
Macedonia
50
5,106
49,133
238
10.4
South Korea
5
12,438
30,176
280
41.2
South Sudan
51
1,882
18,688
34
10.1
Israel
6
20,778
51,835
306
40.1
Pakistan
52
181,088
1,908,427
3,590
9.5
Norway
7
8,708
25,098
244
34.7
Italy
53
238,499
2,533,481
34,634
9.4
Estonia
8
1,981
5,896
69
33.6
Netherlands
54
49,593
538,868
6,090
9.2
Serbia
9
12,894
38,735
261
33.3
El Salvador
55
4,626
53,327
107
8.7
Luxembourg
10
4,120
12,508
110
32.9
Brazil
56
1,085,038
12,484,118
50,617
8.4
Czech R.
11
10,498
32,666
336
32.1
Nicaragua
57
2,014
24,386
64
8.3
Malaysia
12
8,572
27,040
121
31.7
South Africa
58
97,302
1,269,375
1,930
7.7
Portugal
13
39,133
127,864
1,530
30.6
Hungary
59
4,102
54,281
572
7.6
Japan
14
17,916
61,665
953
29.1
Suriname
60
314
4,170
8
7.5
Austria
15
17,285
61,817
690
28.0
U.K.
61
304,331
4,151,851
42,632
7.3
Lithuania
16
1,798
6,497
76
27.7
India
62
425,282
6,033,057
13,699
7.0
Germany
17
190,359
699,154
8,885
27.2
Belgium
63
60,550
861,976
9,696
7.0
Finland
18
7,143
26,402
326
27.1
Philippines
64
30,052
438,038
1,169
6.9
U. Arab E.
19
44,925
178,155
302
25.2
Iran
65
204,952
3,050,048
9,623
6.7
Cuba
20
2,312
9,281
85
24.9
Colombia
66
68,652
1,030,695
2,237
6.7
Ukraine
21
36,560
148,376
1,002
24.6
France
67
160,377
2,515,344
29,640
6.4
Chile
22
242,355
991,336
4,479
24.4
D. R. Congo
68
5,826
98,916
130
5.9
Croatia
23
2,317
9,957
107
23.3
Cameroon
69
11,610
199,080
301
5.8
Denmark
24
12,391
53,638
600
23.1
Bolivia
70
24,388
424,522
773
5.7
Greece
25
3,266
14,533
190
22.5
Somalia
71
2,779
49,186
90
5.7
Poland
26
31,931
150,582
1,356
21.2
Afghanistan
72
28,833
565,246
581
5.1
Switzerland
27
31,209
148,912
1,680
21.0
Indonesia
73
45,891
905,257
2,465
5.1
Saudi Arabia
28
157,612
823,639
1,267
19.1
Nigeria
74
20,244
409,327
518
4.9
Turkey
29
187,685
984,358
4,950
19.1
Honduras
75
12,769
263,032
363
4.9
Morocco
30
9,977
55,386
214
18.0
Algeria
76
11,771
242,645
845
4.9
Albania
31
1,927
11,300
44
17.1
Egypt
77
55,233
1,182,338
2,193
4.7
Bulgaria
32
3,905
23,586
199
16.6
Ecuador
78
50,640
1,084,641
4,223
4.7
Bangladesh
33
112,306
678,767
1,464
16.5
Kenya
79
4,738
109,829
123
4.3
Slovenia
34
1,520
9,410
109
16.2
Libya
80
544
12,846
10
4.2
U.S.
35
2,280,912
14,248,772
119,975
15.7
Sierra Leone
81
1,327
31,692
55
4.2
Moldova
36
14,200
93,470
473
15.2
Mauritania
82
2,813
75,687
108
3.7
Bosnia & H.
37
3,354
22,225
169
15.1
Guatemala
83
13,145
398,078
531
3.3
Panama
38
26,030
180,819
501
14.4
Sudan
84
8,580
276,728
521
3.1
Argentina
39
42,772
303,341
1,011
14.1
Burkina Faso
85
903
30,773
53
2.9
Romania
40
24,045
177,775
1,512
13.5
Mali
86
1,961
73,306
111
2.7
Dominican R.
41
26,677
197,251
662
13.5
Niger
87
1,036
39,912
67
2.6
Tunisia
42
1,157
9,144
50
12.7
Mexico
88
180,545
7,666,945
21,825
2.4
China
43
84,572
668,564
4,639
12.6
Chad
89
858
43,988
74
2.0
Ireland
44
25,379
208,366
1,715
12.2
Iraq
90
30,868
1,582,972
1,100
2.0
Canada
45
101,326
845,149
8,430
12.0
Yemen
91
941
203,732
256
0.5
Haiti
46
5,211
44,065
88
11.8
Countries are ranked by the detection rates of SARS-CoV-2 infections as of 22 June. Source: Own elaboration.
Non-synchronic descriptive statistics as of 22 June.Countries are ranked by the detection rates of SARS-CoV-2 infections as of 22 June. Source: Own elaboration.
Unconditional Analysis
In this analysis, we show the unconditional relationship between detection rates and deaths. The fitted lines in Figure 6 are obtained after regressing the natural logarithm of the cumulative number of deaths in the country i on their estimated cumulative detection rates (DR). The results strongly suggest a negative relationship between detection rates and the cumulative number of deaths. This strong negative slope is in concordance with the hypothesis that, by detecting a higher proportion of the SARS-CoV-2 infected population, many lives can be saved, in particular, the lives of the elderly and those individuals with preexisting conditions.
Figure 6
Linear prediction for the natural logarithm of the cumulative number of deaths from a linear regression of ln(deaths) on the detection rates (DR) 15 and 120 days after the pandemic outbreak (PO). (A) Detection rates and deaths 15 days after the PO. (B) Detection rates and deaths 120 days after the PO. (A) contains all 91 countries (in Table 1A). (B) contains all 61 countries (in Table 1A) whose pandemic processes have more than 120 days since the PO. The dashed fitted line excludes South Korea (KR). Source: Own elaboration.
Linear prediction for the natural logarithm of the cumulative number of deaths from a linear regression of ln(deaths) on the detection rates (DR) 15 and 120 days after the pandemic outbreak (PO). (A) Detection rates and deaths 15 days after the PO. (B) Detection rates and deaths 120 days after the PO. (A) contains all 91 countries (in Table 1A). (B) contains all 61 countries (in Table 1A) whose pandemic processes have more than 120 days since the PO. The dashed fitted line excludes South Korea (KR). Source: Own elaboration.The strong association between the number of deaths and the estimated cumulative detection rates remains significant 15, and 120 days after the PO. These associations are shown in Figures 6A,B, respectively.Figure 7 shows the relationship between detection rates (15 and 120 days after the PO) and deaths 120 days after the PO. This descriptive result is of interest since it suggests that, unconditionally, early detection is associated with death outcomes 120 days after the PO to a greater extent than the contemporary detection rates, that is, 120 days after the PO.
Figure 7
Linear prediction for the natural logarithm of the cumulative number of deaths 120 days after the pandemic outbreak (PO) from a linear regression of ln(deaths) on the detection rates (DR) 15 and 120 days after the PO. (A) Deaths reported 120 days after the PO, and detection rates estimated 15 days after the PO. (B) Deaths reported 120 days after the PO, and detection rates 120 days after the PO. Note: This figure contains all 61 countries (in Table 1A) whose pandemic processes have more than 120 days since the pandemic outbreak. Source: Own elaboration.
Linear prediction for the natural logarithm of the cumulative number of deaths 120 days after the pandemic outbreak (PO) from a linear regression of ln(deaths) on the detection rates (DR) 15 and 120 days after the PO. (A) Deaths reported 120 days after the PO, and detection rates estimated 15 days after the PO. (B) Deaths reported 120 days after the PO, and detection rates 120 days after the PO. Note: This figure contains all 61 countries (in Table 1A) whose pandemic processes have more than 120 days since the pandemic outbreak. Source: Own elaboration.Although this information suggests the existence of a strong relationship between detection rates and the cumulative number of deaths, this slope may be confounded by the variables mentioned before. Thus, in the next section, we show the results of our conditional analysis as described earlier.
Multivariate Regression Analysis
Our results in Table 4 show that higher detection rates are associated with a reduction in the number of deaths after controlling for demography (age-structure of the population and population size), economic performance (GDP per capita), and the relative resources that the economies devote to their health systems. Over time, the cross-sectional regressions increase in explanatory power, from a R-squared of 0.71 in model 2 to 0.95 in model 8.
Table 4
Synchronic multiple linear regression of the natural logarithm of the cumulative number of deaths on the estimated detections rates.
Estimated detection rate 15 days after PO (squared)
–
–
–
–
47.64*
–
–
35.63
–
–
–
–
(28.54)
–
–
(24.01)
Infection fatality rate
0.960***
0.922***
1.586***
1.512***
1.396***
1.525***
1.506***
1.439***
(0.333)
(0.328)
(0.267)
(0.270)
(0.370)
(0.172)
(0.179)
(0.329)
Population size (Ln)
−0.150**
−0.146**
−0.0285
−0.0179
0.0105
0.0699**
0.0649*
0.0267
(0.0656)
(0.0688)
(0.0856)
(0.0780)
(0.0787)
(0.0345)
(0.0356)
(0.0518)
Confirmed cases (Ln)
0.860***
0.773***
0.943***
0.910***
0.705***
0.931***
0.929***
0.849***
(0.0995)
(0.108)
(0.0696)
(0.0640)
(0.0796)
(0.0324)
(0.0334)
(0.0639)
GDP per capita (Ln)
−0.446***
−0.417***
0.0399
0.0570
0.0742
0.181***
0.168**
−0.0194
(0.108)
(0.103)
(0.0842)
(0.0913)
(0.138)
(0.0600)
(0.0642)
(0.154)
Health spending as % of GDP
−0.0570*
−0.0552
−0.0147
−0.0270
−0.000955
0.00186
−0.0115
0.00210
(0.0330)
(0.0354)
(0.0231)
(0.0260)
(0.0277)
(0.0143)
(0.0163)
(0.0312)
BCG group 2
–
−0.441
–
0.175
0.124
–
0.185*
0.196
–
(0.323)
–
(0.161)
(0.206)
–
(0.101)
(0.233)
BCG group 3
–
−0.396
–
0.0449
−0.0185
–
0.185
0.197
–
(0.284)
–
(0.235)
(0.305)
–
(0.165)
(0.332)
BCG group 4
–
−0.704***
–
−0.193
−0.205
–
−0.0324
−0.131
–
(0.220)
–
(0.184)
(0.209)
–
(0.102)
(0.213)
BCG group 5
–
−0.411*
–
−0.172
−0.175
–
0.0200
0.0653
–
(0.210)
–
(0.152)
(0.176)
–
(0.0856)
(0.178)
Constant
4.530***
5.355***
−2.365
−2.204
−1.313
−5.437***
−5.174***
−2.425*
(1.391)
(1.434)
(1.431)
(1.442)
(1.629)
(0.679)
(0.776)
(1.362)
Observations
87
87
84
84
84
74
74
74
R-squared
0.672
0.708
0.950
0.954
0.934
0.984
0.985
0.954
R-squared adjusted
0.643
0.666
0.945
0.947
0.924
0.983
0.983
0.946
F-test
26
21.86
342.3
274.9
110.5
594.5
404.1
137.8
Standard errors in parentheses. Significance levels:
p < 0.01,
p < 0.05,
p < 0.1. Source: Own elaboration.
Synchronic multiple linear regression of the natural logarithm of the cumulative number of deaths on the estimated detections rates.Standard errors in parentheses. Significance levels:p < 0.01,p < 0.05,p < 0.1. Source: Own elaboration.Based on these results, Figure 8 shows a strong conditional gradient between detection rates and the cumulative number of deaths. For instance, for a hypothetical country with average and constant endowments, the cost in terms of deaths of detecting 5% vs. 35% is about 1.81 natural logarithm points which corresponds to exp1.81 = 6.13. That is, the average country detecting 5% is associated with a number of deaths about 6.1 times higher when compared with the same country detecting 35% of all SARS-CoV-2 infections.
Figure 8
Predictive Margins of the cumulative number of deaths at different detection rates of SARS-CoV-2 infections after 120 days of the pandemic outbreak. Source: Own elaboration.
Predictive Margins of the cumulative number of deaths at different detection rates of SARS-CoV-2 infections after 120 days of the pandemic outbreak. Source: Own elaboration.To put this result in perspective, let us simulate what would be the number of deaths in the U.S., if instead of detecting 16.02% 120 days after the pandemic outbreak, the country would have detected with the same intensity as South Korea (41.01%). Evaluating the number of deaths at the endowments of the U.S, the country would have fewer deaths by 1.14 natural logarithm points. It means that the current U.S deaths are now 3.13 times higher than they would be if the country would have tested with similar intensity as South Korea. Since the number of deaths 120 days after the pandemic outbreak reached 126,140, detecting at the rate of South Korea would have saved about 85,794 lives in the U.S. at that time.Finally, looking at the regression coefficients in Table 3, it is noteworthy the fact that during the pandemic outbreak, a 1% higher detection rate is associated with more lives saved than a 1% increase in the health expenditure over the GDP. Our results also suggest that the number of deaths, rather than depending on the relative solvency of the health system, could depend in a greater extent on the size and opportunity of the testing efforts.The conclusion is the more tests the better. Although in this study we employed an economics inspired approach to figure out the importance of testing, our findings are also endorsed by recent medical literature on coronavirus as well as by another economics inspired models providing support to a causal relationship between detection and saving lives (47–50).
Robustness of the Results
Robust regressions provide estimates that are close to the ones reported in Table 4. Consequently, it is unlikely that the results reported in this study are outlier driven. Additionally, results are robust to heteroscedasticity of unknown form for small samples. Nevertheless, results should be interpreted with caution. The few observations available for the regressions and lack of data does not allow to rule out the possibility that there are omitted variables that have the potential to bias the results.It is important to keep in mind that results can be biased if omitted variable problem exists. That is, there are variables that are correlated with the explained outcome but at the same time they are also correlated with the explanatory variables of interest. For instance, one can think in countries implementing lockdowns because lower detection rates (Argentina), or relaxed social distancing rules because higher detection rates (Australia). Nevertheless, these non-observed variables yield to an underestimation of the true association between detection rates and the cumulative number of deaths. Thus, detection matters.
Discussion
In this study, we have proposed a method to estimate the number of SARS-CoV-2 infections for the globe and also for all 91 major countries covering more than 86% of the world population. On June 22, we find that, worldwide, about 160 million individuals have been infected by SARS-CoV-2. Moreover, only about 1 out of 11 these infections have been detected. We find that detection rates are very unequally distributed across the globe and that they also increased over time from about 1% during the second and third weeks of March to about 9% on June 22. In an information context in which population-based seroepidemiological studies are not available, this study shows a parsimonious alternative to provide estimates of the number of SARS-CoV-2 infected individuals. By comparing our estimates with those provided by the ENE-COVID study in Spain, we confirm the utility of our approach keeping in mind that from the public health point of view, it is preferable to be vaguely right than precisely wrong.In order to provide reliable estimates of the number of SARS-CoV-2 infections and of the cumulative detection rates, it is necessary that governments provide real-time information about the number of COVID-19deaths. This study supports the view that an accurate communication of the fatality cases can have consequences on the development of the pandemic itself. Thus, it is also a call for allowing international comparison following WHO international norms and standards for medical certificates of COVID-19 cause of death and International Classification of Diseases (ICD) mortality coding.Additionally, in our empirical analysis, we have presented parsimonious evidence, that higher detection rates are associated with saving lives. Our conditional analysis shows, for example, that if the US would have had the same detection rate trajectory as South Korea, about two-thirds of the reported deaths could have been avoided (about 85,000 lives).We find that detection rates at the very early stages of the pandemic seem to explain the great divergence in terms of deaths between countries. Moreover, we showed evidence that moving from relatively low to high cumulative detection rates (and thus saving lives) is unlikely and difficult. This is probably due to the high level of efforts needed to expand testing relative to the exponentially growing infections at the early and middle stages of the pandemic. Thus, from the public health point of view, it is better to deploy testing efforts at the first stages of the pandemic process. To do this would be much more advantageous, in terms of saved lives, but also it would be technically, and economically feasible.Already, many developed countries with well-developed health sectors were not able to avoid unnecessary deaths by their inaction in terms of promoting mass testing to counter the pandemic outbreak at early stages.To achieve the goal of implementing mass testing from the very beginning of the pandemic outbreak, governments need to understand the consequences of not doing that. Thus, the evidence presented in this paper offers a rigorous macro-level linkage between detection rates and the cumulative number of deaths which may be useful in future pandemics. This evidence also supports the implementation of mass testing in the likely coming secondary pandemic outbreak (so-called second waves).Further research should be devoted to understanding why the detection capacity in many advanced countries was too weak, late, and also so weakly correlated (if correlated) with the income levels. In this paper, we claim that governments have incentives against test because the public opinion tends to primarily react to the report of the cumulative and the marginal numbers of detected (reported) cases. The contradiction is that something good, such as the increase in the testing efforts by governments, can be perceived by the general public as something negative (due to the increase in detections). In consequence, are low detection rates in developed countries simply a management failure, or are there long-run incentives that promoted this behavior among many rich countries? It is clear that during the ongoing pandemic, improving detection rates is a race against time, but are there institutional and/or technological constraints that hamper detection improvements that can save lives? All these questions are relevant for this and future pandemics. This study claims that all countries in the world should be able to respond to a pandemic outbreak with massive testing in the very short run. This would be an efficient approach since it is also likely that higher detection rates are also associated with a lesser impact of the pandemic on the economy.
Data Availability Statement
The raw data supporting the conclusions of this article will be made available by the authors, without undue reservation.
Author Contributions
CV conceived this research, performed the background work, collected the data, performed all statistical analyses, and wrote the paper.
Conflict of Interest
The author declares that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Table 1B
Synchronic descriptive statistics (60, 75, and 90 days after the pandemic outbreak).
Country/Days since the first 100 cases were confirmed
Detection rankings
Confirmed Cases (in thousands)
Estimated Cases (in thousands)
Estimated detection rate (Percentage)
Number of deaths (Count)
60
75
90
60
75
90
60
75
90
60
75
90
60
75
90
South Korea
6
7
6
10.7
10.8
11.1
26.9
27.9
28.8
39.7
38.7
38.6
236
254
263
Australia
1
1
1
6.9
7.1
7.3
10.8
10.8
11.0
63.8
65.7
65.9
97
101
102
Luxembourg
8
9
10
3.9
4.0
4.1
12.4
12.4
12.4
31.7
32.5
32.9
104
110
110
Thailand
3
4
4
3.0
3.1
3.1
7.3
7.3
7.3
41.4
42.0
42.9
56
57
58
Lithuania
14
16
15
1.6
1.7
1.8
6.1
6.4
6.5
25.8
26.4
27.6
60
71
76
Croatia
16
18
22
2.2
2.2
2.3
8.8
8.8
9.5
25.4
25.4
23.7
95
103
107
Estonia
9
10
9
1.7
1.8
2.0
5.9
5.9
5.9
29.6
31.2
33.4
61
66
69
Norway
7
8
8
7.8
8.3
8.4
23.3
24.0
24.7
33.6
34.3
34.1
208
233
237
Finland
19
19
17
6.0
6.6
7.0
25.6
26.1
26.3
23.3
25.3
26.7
267
308
324
Israel
5
6
5
16.5
16.8
18.4
41.0
42.7
45.9
40.3
39.3
40.0
258
281
299
Czech R.
10
11
12
8.1
9.0
9.8
29.6
30.5
32.1
27.5
29.5
30.4
280
317
328
Japan
13
12
14
11.1
15.4
16.4
42.8
54.5
57.6
26.0
28.2
28.5
186
543
777
Greece
24
25
24
2.7
2.9
3.1
13.4
14.0
14.3
20.3
20.6
21.3
151
172
183
Chile
27
33
27
37.0
90.6
167.4
209.2
608.1
866.7
17.7
14.9
19.3
358
944
3,101
Austria
12
13
16
15.7
16.3
16.8
58.1
58.9
61.0
26.9
27.7
27.5
608
633
672
Bosnia & H.
35
34
36
2.3
2.6
3.3
16.0
17.6
21.7
14.6
14.7
15.1
135
158
168
Albania
20
26
31
1.0
1.2
1.9
4.2
6.4
11.1
23.0
18.9
17.0
31
33
43
Slovenia
31
32
33
1.5
1.5
1.5
9.1
9.2
9.4
16.0
16.0
15.9
102
106
109
Bulgaria
33
35
34
2.2
2.5
3.5
14.1
17.7
22.2
15.8
14.2
15.6
110
144
181
Puerto Rico
11
5
3
3.3
5.3
6.9
12.2
12.8
15.3
27.2
41.7
44.9
129
143
151
Cuba
22
20
19
2.0
2.2
2.3
9.0
9.1
9.3
21.7
24.2
24.9
82
83
85
Malaysia
15
15
11
6.5
7.1
8.3
25.4
26.7
26.7
25.5
26.7
31.1
107
115
117
Tunisia
41
43
42
1.0
1.1
1.2
8.9
9.0
9.1
11.8
12.0
12.7
47
49
50
Serbia
2
2
7
10.6
11.4
12.4
24.3
25.5
34.2
43.7
44.8
36.4
230
244
256
Portugal
17
14
13
27.7
31.0
35.6
109.6
115.5
121.1
25.2
26.9
29.4
1,144
1,342
1,495
Switzerland
23
24
25
29.9
30.5
30.8
145.4
147.8
148.4
20.6
20.7
20.8
1,476
1,613
1,659
Moldova
39
38
35
6.7
9.2
14.0
55.1
73.4
89.8
12.2
12.6
15.5
233
323
464
South Africa
64
60
55
14.4
32.7
73.5
304.5
592.7
1,015.7
4.7
5.5
7.2
261
683
1,568
Ukraine
21
21
21
20.6
27.0
37.2
91.7
119.4
151.1
22.4
22.6
24.6
605
788
1,012
Macedonia
48
51
47
1.9
2.6
4.8
20.9
33.8
46.6
8.9
7.7
10.3
110
147
222
Denmark
25
22
23
10.1
11.2
11.9
50.2
52.5
53.2
20.1
21.4
22.4
514
561
587
El Salvador
46
49
–
2.9
4.6
–
31.1
53.3
–
9.4
8.7
–
53
107
–
Panama
37
37
37
9.4
13.5
21.4
73.6
99.2
151.6
12.8
13.6
14.1
269
336
448
Poland
30
29
26
16.9
22.5
28.2
105.0
125.4
142.1
16.1
17.9
19.8
839
1,028
1,215
Argentina
52
45
40
7.8
17.4
34.1
106.9
161.7
254.4
7.3
10.8
13.4
366
556
878
Bangladesh
38
31
32
57.6
105.5
159.7
460.1
638.5
965.1
12.5
16.5
16.5
781
1,388
1,997
Russia
4
3
2
262.8
396.6
529.0
639.9
896.2
1,146.1
41.1
44.2
46.2
2,418
4,555
6,948
Guatemala
78
76
–
7.1
13.8
–
239.1
417.0
–
3.0
3.3
–
252
547
–
China
29
40
43
81.1
82.4
83.8
480.8
667.4
667.6
16.9
12.3
12.5
3,241
3,316
4,636
Romania
36
36
41
15.8
18.6
21.2
119.2
136.2
158.9
13.2
13.7
13.3
1,002
1,219
1,369
Turkey
28
28
28
148.1
163.9
179.8
853.5
906.0
956.9
17.3
18.1
18.8
4,096
4,540
4,825
Saudi Arabia
26
27
30
44.8
80.2
119.9
227.4
435.6
678.5
19.7
18.4
17.7
273
441
893
Germany
18
17
18
157.6
172.2
180.5
626.6
662.7
680.8
25.2
26.0
26.5
6,115
7,723
8,450
Haiti
40
–
–
6.1
–
–
51.6
–
–
11.8
–
–
110
–
–
Ireland
42
42
44
23.2
24.8
25.2
198.5
204.4
207.7
11.7
12.1
12.2
1,488
1,631
1,703
Morocco
32
30
29
7.1
8.0
9.6
44.7
46.4
52.7
16.0
17.3
18.2
194
208
213
Dominican R.
43
41
39
13.2
18.0
24.6
116.8
148.3
183.3
11.3
12.2
13.4
441
516
635
Canada
45
44
45
67.7
84.7
96.2
700.1
784.8
820.9
9.7
10.8
11.7
4,693
6,424
7,835
Hungary
53
52
53
3.6
3.9
4.1
50.1
52.4
53.9
7.1
7.5
7.6
467
534
568
Colombia
54
54
60
14.9
29.4
53.1
233.8
429.7
809.2
6.4
6.8
6.6
562
939
1,726
Niger
81
80
–
1.0
1.0
–
38.9
39.5
–
2.5
2.6
–
65
67
–
Pakistan
60
62
52
37.2
66.5
139.2
686.1
1,230.3
1,658.4
5.4
5.4
8.4
803
1,395
2,632
U. Arab E.
34
23
20
21.8
33.9
42.3
145.2
159.4
171.5
15.0
21.3
24.7
210
262
289
Sweden
55
53
50
22.7
30.8
40.8
365.8
417.2
457.6
6.2
7.4
8.9
2,769
3,743
4,542
Ecuador
70
71
71
31.5
38.6
46.8
763.3
890.2
1,027.2
4.1
4.3
4.6
2,594
3,334
3,896
Somalia
57
59
–
2.6
2.9
–
48.0
51.8
–
5.5
5.7
–
88
90
–
Bolivia
62
61
65
8.4
16.9
30.7
160.1
310.3
534.0
5.2
5.5
5.7
293
559
970
Burkina Faso
80
78
74
0.8
0.9
0.9
30.7
30.7
30.9
2.7
2.9
2.9
52
53
53
Honduras
67
74
68
4.4
7.4
15.4
103.6
182.8
316.5
4.2
4.0
4.9
188
290
426
Iraq
82
82
76
3.0
5.5
17.8
124.6
442.8
1,081.1
2.4
1.2
1.6
115
179
496
Sierra Leone
68
–
–
1.4
–
–
33.3
–
–
4.2
–
–
59
–
–
Kenya
79
73
72
2.0
3.7
6.4
68.7
90.8
147.6
2.9
4.1
4.3
64
104
148
Cameroon
73
64
64
5.4
9.2
12.6
158.6
173.4
215.9
3.4
5.3
5.8
177
273
313
D. R. Congo
65
63
63
3.0
4.8
6.9
66.6
89.8
117.8
4.5
5.3
5.9
69
106
167
Algeria
66
69
69
7.5
9.8
11.5
176.2
209.3
237.2
4.3
4.7
4.9
568
681
825
Netherlands
51
50
51
40.8
44.2
46.7
514.4
529.6
534.8
7.9
8.4
8.7
5,082
5,715
5,977
Iran
59
57
61
89.3
107.6
137.7
1,638.3
1,843.7
2,132.3
5.5
5.8
6.5
5,650
6,640
7,451
Mali
83
79
–
1.6
2.0
–
69.4
74.8
–
2.3
2.7
–
94
112
–
Chad
84
–
–
0.9
–
–
44.4
–
–
2.0
–
–
74
–
–
Afghanistan
71
67
66
11.8
22.1
30.2
296.0
443.9
591.6
4.0
5.0
5.1
220
405
675
Peru
49
46
46
84.5
155.7
229.7
1,017.4
1,497.7
2,038.9
8.3
10.4
11.3
2,393
4,371
6,688
Sudan
75
77
–
8.3
9.7
–
266.9
311.7
–
3.1
3.1
–
506
604
–
Philippines
69
68
58
11.4
15.0
24.2
273.5
314.0
358.5
4.2
4.8
6.7
751
904
1,036
Brazil
76
66
54
177.6
411.8
802.8
5,729.2
8,243.9
10,800.0
3.1
5.0
7.4
12,400
25,598
40,919
Indonesia
72
72
70
15.4
24.5
36.4
425.5
583.9
762.3
3.6
4.2
4.8
1,028
1,496
2,048
Italy
50
48
49
187.3
215.9
228.7
2,287.7
2,412.9
2,485.6
8.2
8.9
9.2
25,085
29,958
32,616
Spain
47
47
48
215.2
230.7
239.4
2,381.4
2,247.5
2,345.9
9.0
10.3
10.2
24,824
27,563
27,127
India
63
65
59
82.0
173.8
320.9
1,675.2
3,312.0
4,874.1
4.9
5.2
6.6
2,649
4,971
9,195
Egypt
77
75
73
10.4
20.8
41.3
340.3
614.6
975.5
3.1
3.4
4.2
556
845
1,422
Belgium
56
55
57
50.3
55.8
58.7
823.7
847.7
857.3
6.1
6.6
6.8
7,924
9,108
9,522
Nigeria
74
70
67
8.9
15.2
24.1
266.1
339.2
486.8
3.4
4.5
4.9
259
399
558
France
61
58
62
126.8
140.7
149.1
2,350.2
2,424.9
2,468.3
5.4
5.8
6.0
23,660
27,074
28,662
Mexico
85
81
75
47.1
90.7
150.3
2,899.6
4,823.5
6,766.9
1.6
1.9
2.2
5,045
9,930
17,580
U.K.
58
56
56
186.6
246.4
278.0
3,403.7
3,778.5
3,971.6
5.5
6.5
7.0
28,446
34,796
39,369
U.S.
44
39
38
1,069.8
1,443.4
1,770.4
10,137.1
11,539.1
12,571.5
10.6
12.5
14.1
63,006
87,568
103,781
This ranking is made up of all countries with more than 30 deaths due to COVID-19 40 days after the pandemic outbreak. Countries are ranked by their detection rates 15 days after the pandemic outbreak. Missing values in this table indicate that the country has not reached the requested number of days after its pandemic outbreak. Source: Own elaboration.
Authors: Seth Flaxman; Swapnil Mishra; Axel Gandy; H Juliette T Unwin; Thomas A Mellan; Helen Coupland; Charles Whittaker; Harrison Zhu; Tresnia Berah; Jeffrey W Eaton; Mélodie Monod; Azra C Ghani; Christl A Donnelly; Steven Riley; Michaela A C Vollmer; Neil M Ferguson; Lucy C Okell; Samir Bhatt Journal: Nature Date: 2020-06-08 Impact factor: 49.962
Authors: Yan-Rong Guo; Qing-Dong Cao; Zhong-Si Hong; Yuan-Yang Tan; Shou-Deng Chen; Hong-Jun Jin; Kai-Sen Tan; De-Yun Wang; Yan Yan Journal: Mil Med Res Date: 2020-03-13
Authors: Silvia Stringhini; Ania Wisniak; Giovanni Piumatti; Andrew S Azman; Stephen A Lauer; Hélène Baysson; David De Ridder; Dusan Petrovic; Stephanie Schrempft; Kailing Marcus; Sabine Yerly; Isabelle Arm Vernez; Olivia Keiser; Samia Hurst; Klara M Posfay-Barbe; Didier Trono; Didier Pittet; Laurent Gétaz; François Chappuis; Isabella Eckerle; Nicolas Vuilleumier; Benjamin Meyer; Antoine Flahault; Laurent Kaiser; Idris Guessous Journal: Lancet Date: 2020-06-11 Impact factor: 79.321